%D9%81%D9%88%D8%B1%D9%85%D9%88%D8%AA%D9%8A%D8%B1%D9%88%D9%84_%D9%81%D8%B1%D9%85%D9%88%D8%AA%D8%B1%D9%88%D9%84formoterolBudesonida_formoterolSymbicort%D5%96%D5%B8%D6%80%D5%B4%D5%A5%D5%BF%D5%A5%D6%80%D5%B8%D5%AC%E3%83%96%E3%83%87%E3%82%BD%E3%83%8B%E3%83%89%E3%83%BB%E3%83%9B%E3%83%AB%E3%83%A2%E3%83%86%E3%83%AD%E3%83%BC%E3%83%AB%ED%8F%AC%EB%A5%B4%EB%AA%A8%ED%85%8C%EB%A1%A4%E0%AC%AB%E0%AC%B0%E0%AD%8D%E0%AC%AE%E0%AD%8B%E0%AC%9F%E0%AD%87%E0%AC%B0%E0%AD%8B%E0%AC%B2formoterolformoterolQ863389%E7%A6%8F%E8%8E%AB%E7%89%B9%E7%BD%97
about
sameAs
Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UKSymbicort Onset of Action 1Atlantis SymbicortLong-Term Safety of Symbicort in Asthmatic Children - SAPLINGGemini Symbicort pMDIEfficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUTSymbicort Onset of Action 2A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanEfficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) PatientsA Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical PracticeAssess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.Symbicort Turbuhaler 30/60 Clinical Experience InvestigationSymbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
P921
Q58110015-7BFC7733-5A4A-4530-B92B-FA2EA10F9659Q61914326-377A97D1-0CEA-48E9-8073-25E23E6835B0Q61914329-9C875B1D-79ED-4E00-BA39-73F49A13291CQ61914336-70239BC4-DE99-40AF-87E2-098D791F854EQ61914337-EAA48D5B-2F0F-4BD4-9EC1-7609B4CAD3D3Q61914353-F6CAFABB-859A-46B1-B46B-1C81977FCEA0Q61914376-BB0ED641-CA58-46CA-AC9C-BB66D824598DQ61938764-E20D6AE9-648A-4A50-AEDB-53232C5578ECQ61938944-0EE725A0-02A1-43BC-9C69-9EB57F01B97FQ61979994-D1D4BFB3-774E-4A0E-B0F3-0950E85A16BFQ63338331-864A9962-9090-41D1-BE19-9A8D3DE859B0Q63340895-2DCEBCED-F491-4776-B406-16D8EC95D60EQ63340996-0FBDA00E-0DF2-4D7F-B7DB-6990D4568879
P921
description
combination formulation contai ...... obstructive pulmonary disease
@en
eit kombinasjonsmedikament brukt til behandling av astma og kols
@nn
συνδυαστικό φάρμακο βουδασενίδ ...... ς αποφρακτικής πνευμονοπάθειας
@el
ଏହା ଏକ ମିଶ୍ରିତ ଔଷଧ ଯାହା ଆଜ୍ମା ବା ସିଓପିଡି ରୋଗ ଚିକିତ୍ସାରେ ଦିଆଯାଏ ।
@or
name
Budesonida formoterol
@es
Budesonida/formoterol
@pt
Budesonide/formoterol
@en
Symbicort
@fr
budesonid–formoterol
@nn
sumbicort turbuhaler 320/9
@ka
Βουδεσονίδη/φορμοτερόλη
@el
بوديزونيد/فورموتيرول
@ar
ବୁଡେସୋନାଇଡ/ଫର୍ମୋଟେରୋଲ
@or
ブデソニド・ホルモテロール
@ja
type
label
Budesonida formoterol
@es
Budesonida/formoterol
@pt
Budesonide/formoterol
@en
Symbicort
@fr
budesonid–formoterol
@nn
sumbicort turbuhaler 320/9
@ka
Βουδεσονίδη/φορμοτερόλη
@el
بوديزونيد/فورموتيرول
@ar
ବୁଡେସୋନାଇଡ/ଫର୍ମୋଟେରୋଲ
@or
ブデソニド・ホルモテロール
@ja
altLabel
budesonid og formoterol
@nn
budesonid-formoterol
@nn
budesonid/formoterol
@nn
budesonide / formoterol
@en
ସିମ୍ବିକର୍ଟ
@or
シムビコート
@ja
ホルモテロール・ブデソニド
@ja
부데소니드 포르모테롤
@ko
심비코트 터부헬러
@ko
심비코트
@ko
prefLabel
Budesonida formoterol
@es
Budesonida/formoterol
@pt
Budesonide/formoterol
@en
Symbicort
@fr
budesonid–formoterol
@nn
sumbicort turbuhaler 320/9
@ka
Βουδεσονίδη/φορμοτερόλη
@el
بوديزونيد/فورموتيرول
@ar
ବୁଡେସୋନାଇଡ/ଫର୍ମୋଟେରୋଲ
@or
ブデソニド・ホルモテロール
@ja
P2175
P31
P3780
P486
P6366
P661
P662
P2017
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC ...... NC[C@H](C2=CC(=C(C=C2)O)NC=O)O
P231
150693-37-1
P233
CCCC1OC2CC3C4CCC5=CC(=O)C=CC5( ...... )OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
P234
1S/C25H34O6.C19H24N2O4/c1-4-5- ...... 22+,23-,24-,25+;13-,19+/m00/s1
P235
PJFHZKIDENOSJB-JIVDDGRNSA-N
P267
P3117
DTXSID80872449
P3345
P3780
P486
D000069502
P6366
2777450039